| P50 | author | Gabriela Riemekasten | Q21260007 |
| | Gerd-Rüdiger Burmester | Q47261275 |
| P2093 | author name string | Duska Dragun | |
| | Harald Heidecke | |
| | Mislav Radić | |
| | Jeannine Günther | |
| | Elise Siegert | |
| | Angela Kill | |
| | Mike Oliver Becker | |
| | Judith Rademacher | |
| P2860 | cites work | Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes | Q24647107 |
| | Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines | Q28564355 |
| | Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes | Q32072042 |
| | Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 |
| | Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway | Q33903180 |
| | Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 |
| | The multiple actions of angiotensin II in atherosclerosis | Q34060768 |
| | Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor | Q34099697 |
| | Essential role of Smad3 in angiotensin II-induced vascular fibrosis | Q34575283 |
| | Central role of the AT(1)-receptor in atherosclerosis | Q34761161 |
| | Role of the renin-angiotensin system in vascular inflammation | Q34789029 |
| | Inflammation and angiotensin II. | Q35099157 |
| | Endothelin and endothelin receptor antagonists in systemic rheumatic disease | Q35127435 |
| | Systemic sclerosis: a prototypic multisystem fibrotic disorder | Q35649427 |
| | Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling | Q35681804 |
| | Sequential dermal microvascular and perivascular changes in the development of scleroderma | Q68034596 |
| | Scleroderma (systemic sclerosis): classification, subsets and pathogenesis | Q68330753 |
| | In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease | Q71607968 |
| | Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms | Q72996198 |
| | AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 |
| | Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage | Q74188173 |
| | Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts | Q74573150 |
| | Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors | Q75288461 |
| | CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis | Q80238474 |
| | Autoantibodies against G-protein-coupled receptors modulate heart mast cells | Q80278334 |
| | Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines | Q81072711 |
| | Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis | Q81162536 |
| | Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 |
| | Reduced expression of angiotensin II and angiotensin receptor type 1 and type 2 in resistance arteries from nasal lesions in granulomatosis with polyangiitis (Wegener's granulomatosis) | Q84971305 |
| | Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease | Q35763490 |
| | Is systemic sclerosis an antigen-driven T cell disease? | Q35799608 |
| | Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database | Q35953368 |
| | Is preeclampsia an autoimmune disease? | Q36050775 |
| | Vascular endothelin in hypertension | Q36162950 |
| | Scleroderma: from cell and molecular mechanisms to disease models | Q36259889 |
| | Inflammation in hypertension. | Q36398035 |
| | Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein | Q36470843 |
| | Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. | Q36591603 |
| | Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis | Q36667816 |
| | Genetic factors in systemic sclerosis | Q36927757 |
| | Molecular pathways as novel therapeutic targets in systemic sclerosis | Q36961452 |
| | Regulation of T-cell function by endogenously produced angiotensin II. | Q37100479 |
| | Expression and function of ETA and ETB receptors in SSc. | Q37265814 |
| | Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients | Q37350899 |
| | Non-invasive biomarkers in pulmonary fibrosis | Q37585596 |
| | Cellular and molecular aspects of vascular dysfunction in systemic sclerosis | Q37768336 |
| | Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee | Q39513167 |
| | A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. | Q40328974 |
| | Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. | Q42154997 |
| | CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity | Q42481241 |
| | AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes | Q42489417 |
| | Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 |
| | AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 |
| | Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 |
| | Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? | Q45715684 |
| | Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 |
| | Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism | Q46481430 |
| | Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries | Q46618559 |
| | Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. | Q46986151 |
| | Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis | Q48513015 |
| | Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. | Q52886517 |
| | Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. | Q52900457 |
| | Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 |
| | Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. | Q53568433 |
| | Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 |
| | Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis | Q58234794 |
| P433 | issue | 2 | |
| P921 | main subject | autoantibody | Q785022 |
| P304 | page(s) | R65 | |
| P577 | publication date | 2014-03-11 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients | |
| P478 | volume | 16 | |